MOSCOW (Sputnik) – Pre-clinical trials of Mefloquine show it suppressing the cytopathic effect of the coronavirus within 48 hours in a very small dose, Veronika Skvortsova, the head of the Federal Biomedical Agency, said Friday.
According to the official, the drug lowers the cytopathic effect of the virus by 50-75 percent even when used before the infection, so it could be used as a preventive step.
At least 70 percent of the patients treated with Mefloquine had consistent improvement, Skvortsova added.
Following the outbreak of the coronavirus pandemic, medics put hope in Remdesivir, a drug manufactured by the American biopharmaceutical company Gilead Sciences.
However, the World Health Organisation (WHO) said that the drug failed its first clinical trial.
Sourse: sputniknews.com
0.00 (0%) 0 votes
